{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:07:43Z","timestamp":1750306063389,"version":"3.41.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.gore.2025.101752","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T16:07:53Z","timestamp":1745338073000},"page":"101752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["\u201cFour years of remission with fulvestrant monotherapy in advanced endometrioid adenocarcinoma of the endometrium Harboring an ESR1 Mutation: A case Report\u201d"],"prefix":"10.1016","volume":"59","author":[{"given":"Jo\u00e3o Felipe","family":"Feldmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karoline","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Henrique","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Carvalho","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romulo Loss","family":"Mattedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Payao","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Scaranti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2025.101752_b0005","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. Accessed at https:\/\/seer.cancer.gov\/explorer\/. Last Revised: January 17, 2024;."},{"issue":"13","key":"10.1016\/j.gore.2025.101752_b0010","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3390\/cancers16132458","article-title":"Unsolved issues in the integrated histo-molecular classification of endometrial carcinoma and therapeutic implications","volume":"16","author":"Kuhn","year":"2024","journal-title":"Cancers [internet]."},{"key":"10.1016\/j.gore.2025.101752_b0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2017.07.002","article-title":"Is hormonal therapy effective in advanced endometrial cancer? A systematic review and metaanalysis","volume":"147","author":"Ethier","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gore.2025.101752_b0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2013.02.039","article-title":"Phase II study of Fulvestrant 250 mg\/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie","volume":"129","author":"Emons","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gore.2025.101752_b0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2010.10.015","article-title":"Phase II study of Fulvestrant in recurrent\/metastatic endometrial carcinoma: a gynecologic oncology group study","volume":"120","author":"Covens","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gore.2025.101752_b0030","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2023-005229","article-title":"An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent\/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)","author":"Trozzi","year":"2024","journal-title":"International Journal of Gynecologic Cancer [internet]"},{"issue":"16_suppl","key":"10.1016\/j.gore.2025.101752_b0035","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2024.42.16_suppl.5511","article-title":"A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer","volume":"42","author":"Green","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.gore.2025.101752_b0040","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1186\/s12885-023-11559-x","article-title":"Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma","volume":"23","author":"Drouyer","year":"2023","journal-title":"BMC Cancer [internet]."},{"key":"10.1016\/j.gore.2025.101752_b0045","article-title":"Endometrial endometrioid adenocarcinoma with a malignant squamous component: is the unusual metastatic pattern unique of these tumors?","author":"Ruhul Quddus","year":"2024","journal-title":"Virchows Arch."},{"issue":"3","key":"10.1016\/j.gore.2025.101752_b0050","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/01443615.2021.1916809","article-title":"The prognostic value of squamous differentiation in endometrioid type endometrial cancer: a matched analysis","volume":"42","author":"Aslan","year":"2021","journal-title":"J. Obstet. Gynaecol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:05:32Z","timestamp":1750215932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":10,"alternative-id":["S2352578925000773"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101752","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cFour years of remission with fulvestrant monotherapy in advanced endometrioid adenocarcinoma of the endometrium Harboring an ESR1 Mutation: A case Report\u201d","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101752"}}